From: Jan Drew on
On Oct 31, 3:45 pm, not dr_jeff <u...(a)msu.edu> wrote:
> john wrote:
> >http://preventdisease.com/news/09/102809_9_arguments_to_win_any_vacci...
>
> > 9 Questions That Stump Every Pro-Vaccine Advocate and Their Claims
>
> > Since the flu pandemic was declared, there have been several so-called
> > "vaccine experts" coming out of the wood work attempting to justify the
> > effectiveness of vaccines. All of them parrot the same ridiculous historical
> > and pseudoscientific perspectives of vaccinations which are easily squelched
> > with the following 9 questions.
>
> > Claim: The study of vaccines, their historical record of achievements,
> > effectiveness, safety and mechanism in humans are well understood and proven
> > in scientific and medical circles.
>
> > Fact: The claim is completely false.
>
> > 1. What to ask: Could you please provide one double-blind,
> > placebo-controlled study that can prove the safety and effectiveness of
> > vaccines?
>
> Double-blind study comparing the immunogenicity of a licensed
> DTwPHib-CRM197 conjugate vaccine (Quattvaxem™) with three
> investigational, liquid formulations using lower doses of Hib-CRM197
> conjugate. Eda Tamma, Alessandra Veroneseb, Mario Contornic, Sirli
> Meristea, Pantaleo Naccib, Corresponding Author Contact Information,
> E-mail The Corresponding Author and Simonetta Vivianib.

Who? Where did you not dr--find that name?


Vaccine
> Volume 23, Issue 14, 25 February 2005, Pages 1715-1719.
>
> We performed a double-blind clinical study to evaluate the safety and
> immunogenicity of four formulations of a DTwPHib full liquid vaccine,
> three of which contained fractional doses of the 10 μg-dose of
> CRM197-Hib conjugate vaccine.
>
> A total of 261 infants were enrolled and randomised to receive at 3, 4
> and 5 months of age, in a double-blind fashion, one of the four DTwPHib
> vaccine formulations containing 10, 5, 2.5 or 1.25 μg of CRM197-Hib
> conjugate. Post-immunization reactions were similar in the four vaccine
> groups, they were mild, transient and resolved without sequelae. The
> seroconversion rates to anti-PRP titres ≥ 0.15 μg/mL were 100%, 98%, 97%
> and 98% in the groups 10, 5, 2.5 and 1.25 μg, respectively. The
> seroconversion rates to anti-PRP titres ≥1 μg/mL were 95%, 97%, 88% and
> 90%, again respectively. Anti-PRP GMTs were 18, 17, 7.82 and 6.94 μg/mL,
> respectively. All subjects were protected against tetanus and
> diphtheria, and >80% seroconverted to pertussis.
>
> High, and similar, levels of anti-PRP GMTs were elicited by the
> formulations with 10 and 5 μg of CRM197-Hib conjugate.
>
> Although the formulations with 2.5 and 1.25 μg of CRM197-Hib elicited
> lower levels of anti-PRP GMTs, they were immunogenic and are possible
> candidates for further development.
>
> Keywords: Combined vaccines; Fractional doses Hib vaccine; DTwPHib full
> liquid vaccine
>
> > 2. What to ask: Could you please provide scientific evidence on ANY study
> > which can confirm the long-term safety and effectiveness of vaccines?
>
> Postlicensure Safety Surveillance for Varicella Vaccine
>
> Robert P. Wise, MD, MPH; Marcel E. Salive, MD, MPH; M. Miles Braun, MD,
> MPH; Gina Terracciano Mootrey, DO, MPH; Jane F. Seward, MBBS, MPH; Lisa
> G. Rider, MD; Philip R. Krause, MD
>
> JAMA. 2000;284:1271-1279.

JAMA=Organized medicine liars.
>
> Context  Since its licensure in 1995, the extensive use of varicella
> vaccine and close surveillance of the associated anecdotal reports of
> suspected adverse effects provide the opportunity to detect potential
> risks not observed before licensure because of the relatively small
> sample size and other limitations of clinical trials.
>
> Objectives  To detect potential hazards, including rare events,
> associated with varicella vaccine, and to assess case reports for
> clinical and epidemiological implications.
>
> Design and Setting  Postlicensure case-series study of suspected vaccine
> adverse events reported to the US Vaccine Adverse Event Reporting System
> (VAERS) from March 17, 1995, through July 25, 1998.
>
> Main Outcome Measures  Numbers of reported adverse events, proportions,
> and reporting rates (reports per 100,000 doses distributed).
>
> Results  VAERS received 6574 case reports of adverse events in
> recipients of varicella vaccine, a rate of 67.5 reports per 100,000
> doses sold. Approximately 4% of reports described serious adverse
> events, including 14 deaths. The most frequently reported adverse events
> were rashes, possible vaccine failures, and injection site reactions.
> Misinterpretation of varicella serology after vaccination appeared to
> account for 17% of reports of possible vaccine failures. Among 251
> patients with herpes zoster, 14 had the vaccine strain of varicella
> zoster virus (VZV), while 12 had the wild-type virus. None of 30
> anaphylaxis cases was fatal. An immunodeficient patient with pneumonia
> had the vaccine strain of VZV in a lung biopsy. Pregnant women
> occasionally received varicella vaccine through confusion with varicella
> zoster immunoglobulin. Although the role of varicella vaccine remained
> unproven in most serious adverse event reports, there were a few
> positive rechallenge reports and consistency of many cases with
> syndromes recognized as complications of natural varicella.
>
> Conclusion

By whom?

 Most of the reported adverse events associated with
> varicella vaccine are minor, and serious risks appear to be rare. We
> could not confirm a vaccine etiology for most of the reported serious
> events; several will require further study to clarify whether varicella
> vaccine plays a role. Education is needed to ensure appropriate use of
> varicella serologic assays and to eliminate confusion between varicella
> vaccine and varicella zoster immunoglobulin.
>
> And
>
> The Pediatric Infectious Disease Journal:
> December 1999 - Volume 18 - Issue 12 - pp 1041-1046
> Original Studies
> Postmarketing evaluation of the safety and effectiveness of varicella
> vaccine
> BLACK, STEVEN MD; SHINEFIELD, HENRY MD; RAY, PAULA MS; LEWIS, EDWIN MS;
> HANSEN, JOHN; SCHWALBE, JOAN MS; COPLAN, PAUL SCD; SHARRAR, ROBERT MD,
> MSC; GUESS, HARRY MD, PHD
> Collapse Box
> Abstract
>
> Background. The Oka strain of live attenuated varicella virus was
> licensed for use in healthy children in the United States in March,
> 1995. We report a postmarketing evaluation of the short term safety of
> this vaccine within Kaiser Permanente.
>
> Methods. After licensure varicella vaccination was introduced into the
> preventive care program of the Northern California Kaiser Permanente
> Medical Care Program. Potential adverse events after vaccination with
> varicella vaccine were identified from automated clinical databases of
> hospitalizations, emergency room visits and clinic visits. Deaths were
> identified from automated clinical databases at Kaiser as well as from
> the State death records for California. To evaluate safety, rates of
> diagnosis-specific events in the risk periods were compared with the
> rates of such diagnosis-specific events in two self control and one
> historical control period.
>
> Results. During the study period of April 1, 1995, to December 31, 1996,
> a total of 89 753 adults and children received varicella vaccine. A
> total of 3200 relative risks were calculated, and of these 5 hospital
> diagnostic categories, 9 emergency visit diagnostic categories and 30
> outpatient diagnostic categories demonstrated at least 1 relative risk
> with a P value of <0.05 in 1 or more age groups and in comparisons with
> 1 control period or more. The p value for these tests was not adjusted
> for multiple comparisons. Of these categories 14 demonstrated an
> increased risk either in more than 1 age group or against more than 1
> comparison group. These categories included elective procedures, febrile
> seizure, febrile illness, well child, acute gastroenteritis, varicella,
> congenital anomaly, "rule out sepsis," trauma, viral syndrome, apnea,
> back pain, congenital valvular heart disease and vision evaluation for
> glasses. Of these the outcomes of elective procedure, congenital
> anomaly, congenital valvular heart disease, well child and vision
> evaluation for glasses were judged not to have a biologically plausible
> association with vaccination. A second diagnostic grouping included
> febrile illness, viral illness, febrile seizure and "rule out sepsis."
> In an analysis of these events which adjusted for the concomitant
> administration of M-M-RII vaccine, none of the associations was
> statistically associated with receipt of varicella vaccine. The
> diagnostic category of "rule out sepsis" still had a relative risk of
> 1.95 with P = 0.02. None of the children in the "rule out sepsis"
> category had positive bacteriologic cultures from any other normally
> sterile site. Because of the large number of gastroenteritis cases, we
> reviewed a random sample of 100 exposed and 100 unexposed cases. From
> this review no consistent time association or clustering of any of these
> events was seen in the exposed follow-up time interval. Only
> gastroenteritis and negative evaluations for sepsis were thought to be
> possibly associated with receipt of varicella vaccine. Although there
> was a statistically significant increased risk over the entire 30
> day-period, there was no clustering of these events within the 30-day
> window.
>
> Conclusion.

By Whom??


In this study population of 89 753 children and adults, the
> varicella vaccine (Oka strain, Merck) appeared to have a favorable
> safety profile. In addition rates of varicella-like rash and of
> breakthrough cases were both low and consistent with the rates observed
> in prelicensure studies.

Merck--what a joke.

http://www.npr.org/templates/story/story.php?storyId=18803138


>
> > 3. What to ask: Could you please provide scientific evidence which can prove
> > that disease reduction in any part of the world, at any point in history was
> > attributable to inoculation of population
>
> http://www.upi.com/Health_News/2009/10/22/CDC-Vaccine-reduces-rotavir...


>
> > 4. What to ask: Could you please explain how the safety and mechanism of
> > vaccines in the human body are scientifically proven if their
> > pharmacokinetics (the study of bodily absorption, distribution, metabolism
> > and excretion of


I see not dr--did not go past question 4.

Neither did he get anything correct.

Results 1 - 10 of about 1,140,000 for CDC fraud. (0.35 seconds)

Dr. Viviani received a medicine and surgery degree from Siena
University as well as postgraduate degrees in public health and
laboratory. She holds a two-year postgraduate training degree in field
epidemiology from the CDC and the Istituto Superiore di Sanità.

Did you mean Simonetta Viviani

http://www.npr.org/templates/story/story.php?storyId=18803138

Pharmaceutical giant Merck has agreed to pay more than $670 million to
settle claims it overcharged the government for drugs and bribed
doctors to prescribe its drugs. It's one of the biggest health care
fraud settlements ever.
From: Jan Drew on
On Oct 31, 3:52�pm, Mark Probert <mark.prob...(a)gmail.com> wrote:
> On Oct 31, 2:21�pm, "john" <nos...(a)bt.com> wrote:
>
>
>
>
>
> >http://preventdisease.com/news/09/102809_9_arguments_to_win_any_vacci...
>
> > 9 Questions That Stump Every Pro-Vaccine Advocate and Their Claims
>
> > Since the flu pandemic was declared, there have been several so-called
> > "vaccine experts" coming out of the wood work attempting to justify the
> > effectiveness of vaccines. All of them parrot the same ridiculous historical
> > and pseudoscientific perspectives of vaccinations which are easily squelched
> > with the following 9 questions.
>
> > Claim: The study of vaccines, their historical record of achievements,
> > effectiveness, safety and mechanism in humans are well understood and proven
> > in scientific and medical circles.
>
> > Fact: The claim is completely false.
>
> > 1. What to ask: Could you please provide one double-blind,
> > placebo-controlled study that can prove the safety and effectiveness of
> > vaccines?
>
> http://wps.aw.com/wps/media/objects/14/15269/projects/ch12_salk/index...
>
> http://www.npr.org/templates/story/story.php?storyId=4585992
>
> 1952 The United States reports 57,628 polio cases -- the worst U.S.
> epidemic on record.
>
> -- Dr. Salk and his colleagues develop a potentially safe, injectable
> vaccine against polio. Nearly 15,000 Pittsburgh-area subjects, mostly
> children, receive the vaccine in pilot trials.
>
> -- Salk's former mentor, Dr. Thomas Francis, designs, directs and
> evaluates field trials of the polio vaccine. Unprecedented in their
> scope and size, the trials involve around 1.8 million children from
> the United States, Canada and Finland. They are among the first to use
> the double-blind process that has since become standard.
>
> If your idiot writer could not even get the first one right, why
> bother to continue?
>
> DisMISSED!- Hide quoted text -
>
> - Show quoted text -

From: Jan Drew on
On Oct 31, 3:52�pm, Mark Probert <mark.prob...(a)gmail.com> wrote:
> On Oct 31, 2:21�pm, "john" <nos...(a)bt.com> wrote:
>
>
>
>
>
> >http://preventdisease.com/news/09/102809_9_arguments_to_win_any_vacci...
>
> > 9 Questions That Stump Every Pro-Vaccine Advocate and Their Claims
>
> > Since the flu pandemic was declared, there have been several so-called
> > "vaccine experts" coming out of the wood work attempting to justify the
> > effectiveness of vaccines. All of them parrot the same ridiculous historical
> > and pseudoscientific perspectives of vaccinations which are easily squelched
> > with the following 9 questions.
>
> > Claim: The study of vaccines, their historical record of achievements,
> > effectiveness, safety and mechanism in humans are well understood and proven
> > in scientific and medical circles.
>
> > Fact: The claim is completely false.
>
> > 1. What to ask: Could you please provide one double-blind,
> > placebo-controlled study that can prove the safety and effectiveness of
> > vaccines?
>
> http://wps.aw.com/wps/media/objects/14/15269/projects/ch12_salk/index...

Hmmm. This is not a double-blind placebo controlled study that proved
the question John asked.
>
> http://www.npr.org/templates/story/story.php?storyId=4585992

Neither is that.


>
> 1952 The United States reports 57,628 polio cases -- the worst U.S.
> epidemic on record.
>
> -- Dr. Salk and his colleagues develop a potentially safe, injectable
> vaccine against polio. Nearly 15,000 Pittsburgh-area subjects, mostly
> children, receive the vaccine in pilot trials.

Read the words trials. This is not what John listed.
>

Neither is this thread about Polio
>
> DisMISSED!

You are indeed.

Go to your room.

From: Jan Drew on
> Mark Probert wrote:
>
> <...>
>
From: Jan Drew on
On Oct 31, 4:30�pm,not dr_jeff <u...(a)msu.edu> wrote:
> john wrote:
> > "dr_jeff" <u...(a)msu.edu> wrote in message
>
> > No proper control
> >http://www.whale.to/vaccines/never_unvaccinated_controls.html
> > Efficacy based on antibody fraudhttp://www.whale.to/vaccines/antibody.html
>
> http://content.nejm.org/cgi/content/full/354/1/11shows a double blind
> study of the rotavirus vaccine. So you're wrong.

Massachusetts Medical Society

AMA= organized medicine.

http://www.massmed.org/AM/Template.cfm?Section=Scholarship_Information&CONTENTID=24461&TEMPLATE=/CM/HTMLDisplay.cfm

http://www.massmed.org/AM/Template.cfm?Section=MA_Delegation_to_the_AMA1&Template=/TaggedPage/TaggedPageDisplay.cfm&TPLID=77&ContentID=26200

http://www.massmed.org/AM/Template.cfm?Section=Home6&CONTENTID=32094&TEMPLATE=/CM/ContentDisplay.cfm

Results 1 - 10 of about 60,600 for Massachusetts Medical Society AMA.

So, there is the truth.